Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| MS-ocrelizumab Treated | ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start ocrelizumab: FDA-approved MS drugs | 0 | None | 0 | 15 | 0 | 15 | View |
| MS Untreated | age- and sex-matched untreated MS controls | 0 | None | 0 | 5 | 0 | 5 | View |
| Healthy Control | age- and sex-matched untreated healthy controls | 0 | None | 0 | 5 | 0 | 5 | View |
| MS Interferon-treated | MS with ongoing interferon-beta therapy | 0 | None | 0 | 5 | 0 | 5 | View |